Editorials Pharmacovigilance in developing countries BMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39323.586123.BE (Published 06 September 2007) Cite this as: BMJ 2007;335:462 Article Related content Metrics Responses Peer review Related articles Editorial Ethnicity and adverse drug reactions Published: 18 May 2006; BMJ 332 doi:10.1136/bmj.332.7551.1163 See more Cancer drugs remain FDA approved despite lack of benefit, study finds BMJ December 06, 2016, 355 i6568; DOI: https://doi.org/10.1136/bmj.i6568 Johnson & Johnson is ordered to pay $1bn over faulty hip implants BMJ December 06, 2016, 355 i6551; DOI: https://doi.org/10.1136/bmj.i6551 Bill to boost medical research funding and speed drug approval passes US house BMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498 Trial of novel leukaemia drug is stopped for second time after two more deaths BMJ November 25, 2016, 355 i6376; DOI: https://doi.org/10.1136/bmj.i6376 Promise of new Alzheimer’s drug is dashed after lack of evidence BMJ November 24, 2016, 355 i6362; DOI: https://doi.org/10.1136/bmj.i6362 Cited by... Leveraging Experience From Active TB Drug-Safety Monitoring and Management for Monitoring Active Antiretroviral ToxicityFulltext PDF Advancing Global Health Research Through Digital Technology and Sharing DataFulltext PDF Abstract
